Skip to search formSkip to main contentSkip to account menu

ruxolitinib

Known as: (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile 
An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (1)

INCB018424

Narrower (2)

Jakafiruxolitinib phosphate
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibitionruxolitinib 10 MG Oral Tablet [Jakafi]ruxolitinib 20 MG Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors
Myeloid hematological malignancies are clonal bone marrow neoplasms, comprising of acute myeloid leukemia (AML), the… 
2017
2017
A life‐threatening ruxolitinib discontinuation syndrome
CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, Azienda Ospedaliero-Universitaria Careggi, Florence… 
2016
2016
Identification of TBK1 and IKKε, the non-canonical IκB kinases, as crucial pro-survival factors in HTLV-1-transformed T lymphocytes.
2015
2015
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is initiated and driven by the oncogenic fusion protein… 
Review
2015
Review
2015
Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
Background: Ruxolitinib, a Janus kinase (JAK) 1/2 inhibitor, has been approved for the treatment of disease-related splenomegaly… 
Highly Cited
2014
Highly Cited
2014
A randomized double-blind phase 2 study of ruxolitinib (RUX) or placebo (PBO) with capecitabine (CAPE) as second-line therapy in patients (pts) with metastatic pancreatic cancer (mPC).
4000 Background: Local and systemic inflammation (INFL) are hallmarks of cancer, including PC, that adversely impact prognosis… 
Review
2014
Review
2014
Rationale for combination therapy in myelofibrosis.
Highly Cited
2013
Highly Cited
2013
Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
Ruxolitinib, a JAK1/JAK2 inhibitor, is currently the only pharmacological agent approved for the treatment of myelofibrosis… 
Review
2013
Review
2013
Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy
Background Myelofibrosis (MF) is characterized by progressive bone marrow (BM) fibrosis and ineffective, extramedullary… 
2013
2013
Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R
Acquired mutations in the colony-stimulating factor 3 receptor gene ( CSF3R ), truncating the cytosolic region of the CSF3R… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)